Every month, in commercial operations teams across Latin America's pharmaceutical industry, the same ritual plays out. Sales data lands in a folder. Spreadsheets open. A senior analyst starts reconciling rows. By the time the commission cycle closes, the team has spent somewhere around 90 hours on what should be a mechanical task.
Ninety hours is the number we keep seeing — across labs with 30 reps and labs with 300. It's the time cost of manual commission management in pharma. And it's not the real cost.
Where the 90 hours actually go
It's tempting to assume "90 hours" is one long calculation. It's not. Break it down and four distinct buckets emerge — each one preventable, and each one eating different senior time.
1. Calculations (≈ 30–40 hours)
Pulling data from the CRM, the ERP, IQVIA or CloseUp, maybe a shipping system, and occasionally a regional spreadsheet. Normalizing it. Running the commission rules manually — quotas by product, tiered bonuses, coverage targets, line bonuses, regional multipliers. Every change to a rule mid-quarter means the whole engine rebuilds in Excel.
2. Corrections (≈ 15–25 hours)
Errors surface. A SKU is missed. A product launch is miscategorized. A rep's territory changed mid-cycle and the old quota still applied. The corrections aren't the hard part — finding them is. Senior analysts reopen the same workbooks three times in a cycle.
3. Clarifications (≈ 15–20 hours)
"Why did I get paid less this month?" arrives in the commercial ops inbox. Sometimes it's legitimate. Sometimes it's a rep's own back-of-envelope spreadsheet disagreeing with the official one. Either way, someone has to walk through the calculation line by line. Multiply that by a percentage of the sales force, and you've lost two full days.
4. Reconciliation and handoffs (≈ 10–15 hours)
Payroll wants a signed-off file. Finance wants accruals. Internal audit wants a log of every manual override. None of these reports exist in one place until someone stitches them together.
"Our commercial ops team was spending more time defending the numbers than using them. That's the real signal something's broken."
The hours aren't the real cost
If this were just about 90 hours of analyst time, you could solve it with a temp or outsourced processing. It isn't. Manual commission cycles compound into four costs that don't show up on a line item:
- Payment errors. In the pharma and medical device engagements we see, 3–10% of commission users end up paid incorrectly at least once per quarter. That's not a disaster in isolation — it's a disaster culturally. A rep who catches a pay error once stops trusting the next payslip.
- Rep turnover. Commercial leaders consistently cite pay transparency as one of the top three reasons reps leave in this industry. "They left for more money" is often closer to "they left because they didn't trust the money."
- Distracted senior time. The people spending those 90 hours are almost always your most experienced commercial analysts. They should be running productivity reviews, identifying underperforming territories, and helping the VP of Sales plan the next cycle. Instead, they're chasing down CSV files.
- Slower strategic moves. The labs that process commissions manually also take the longest to change incentive plans mid-year. Rolling out a new product-line bonus becomes a months-long project. Competitors who can recalibrate plans in days gain a structural edge.
A pragmatic financial framing: for every 50 reps on a manual process, the direct cost of reprocessing, correcting, and explaining commissions lands around $45,000 USD a year. That number understates the indirect cost — the turnover, the distraction, the lost strategic velocity.
What "good" commission operations actually look like
The labs that have moved past this pattern share four characteristics. None of them is a software buy by itself.
- A single, auditable calculation layer. One engine runs every rule, logs every input, and produces a trail that finance, audit, and the rep themselves can trace. When a rep asks "why," the answer is one click away, not a two-day investigation.
- Self-service for reps, not just admins. Reps see their progress against quota in real time. The guessing-game spreadsheet dies. Payday disputes drop toward zero because the official number is also the most up-to-date number.
- Plan flexibility without re-platforming. New incentive rules — a product-launch bonus, a regional multiplier, a quarterly SPIF — go live in days, not quarters. The commercial leader stops saying "we can't change that this year."
- Dedicated time for commercial strategy. The senior analyst time that used to disappear into spreadsheets is reinvested into territory reviews, deal coaching, and plan design. This is where the real ROI shows up — not in the 90 hours saved, but in the 90 hours redeployed.
Four questions to ask on Monday morning
You don't need a software vendor to start moving on this. You need to ask four questions inside your own commercial operation:
- In the last cycle, how many reps received an incorrect payout? If you don't know, that is the answer.
- How long does it take, on average, to resolve a commission dispute from the moment the rep raises it? If it's more than 24 hours, your calculation is not traceable enough.
- If leadership asked to change the commission plan for one product line starting next month, could you do it? If the answer is "not without chaos," your plan flexibility is the bottleneck.
- What is your senior commercial analyst spending 80% of their week on? If it's commissions, they're not doing the job you hired them for.
Commissions as a strategic function, not a payroll task
The most valuable commercial operations teams in pharma don't treat commissions as a monthly closing process. They treat compensation as a strategic lever — a way to align the sales force with the company's priorities for the next quarter. That shift is not possible when 90 hours a month disappear into spreadsheet archaeology.
If you're reading this and recognizing your own month, the first step isn't buying software. It's auditing where those 90 hours are going and deciding which of the four buckets is costing you the most. The hours are the visible signal. The trust, the turnover, and the strategic drag are the invisible ones — and those are what's actually worth fixing.
Carlos Paternina is the founder and CEO of Bluite, which automates sales incentive and commission processes for pharmaceutical and medical device companies across Latin America. If you'd like to compare notes on any of the questions above, reach out.